Artificial Intervertebral Disc: Lumbar Spine

Policy #  00145
Original Effective Date:  01/31/2005
Current Effective Date:  11/01/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Artificial Intervertebral Disc: Cervical Spine is addressed in medical policy number 00229.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider lumbar artificial intervertebral disc replacement to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility will be considered when ALL of the following criteria are met:

- Age 18 to 60 years old; AND
- Primary complaint of axial pain to be of discogenic origin; AND
- Symptoms for at least one year, which have not responded to a multifaceted program of conservative treatment over that period of time; AND
- Presence of single level, advanced disc disease at L4-5 or L5-S1, as documented by magnetic resonance imaging (MRI) and plain radiographs demonstrating moderate to severe degeneration of the disc with Modic changes (peridiscal bone signal above and below the disc space in question); AND
- Absence of disease at all other lumbar levels, as documented by normal radiographs, and magnetic resonance imaging (MRI) showing no abnormalities or mild degenerative changes; AND
- Absence of contraindications listed below.

Contraindications to lumbar artificial disc replacement (LADR) are:

- Significant facet arthropathy at the operated level;
- Disease above L4-L5;
- Bony lumbar spinal stenosis;
- Pars defect;
- Clinically compromised vertebral bodies at affected level due to current or past trauma;
- Lytic spondylolisthesis or degenerative spondylolisthesis of grade greater than 1;
- Allergy or sensitivity to implant materials (cobalt, chromium, molybdenum, polyethylene, titanium);
- Presence of infection or tumor;
- Osteopenia or osteoporosis (defined as dual-energy x-ray absorptiometry [DEXA] bone density measured T-score less than -1.0).
When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

The use of lumbar artificial intervertebral disc replacement when patient selection criteria are not met is considered to be investigational.*

Based on review of available data, the Company considers lumbar artificial intervertebral disc replacement to be investigational*, including but not limited to the following:

- Disc replacement at more than one spinal level; OR
- Arthroplasty below, or in combination with, spinal fusion or other stabilizing-type procedure; OR
- Isolated radicular compression syndromes, especially due to disc herniation; OR
- Hybrid lumbar total disc arthroscopy (TDA)/Lumbar Fusion (lumbar TDA at one level at the same time as lumbar fusion at a different level); OR
- Arthroplasty using devices other than those which are U.S. Food and Drug Administration (FDA) approved, or use of an FDA-approved device in a manner which does not meet FDA requirements.

Background/Overview

Lumbar disc arthroplasty, also known as lumbar artificial disc surgery or TDA, was developed as an alternative to lumbar fusion for treatment of back pain due to severe degenerative disc disease.

The procedure is similar to lumbar interbody fusion, in that an anterior approach is required. Unlike fusion, motion at the level of disc replacement is maintained, which would seem to be advantageous in terms of preventing secondary degenerative changes and preserving spine mechanics.

Conservative management should include a combination of strategies to reduce inflammation, alleviate pain, and improve function, including but not limited to the following:

- Prescription strength anti-inflammatory medications and analgesics;
- Adjunctive medications such as nerve membrane stabilizers or muscle relaxants;
- Physician-supervised therapeutic exercise program or physical therapy;
- Manual therapy or spinal manipulation;
- Alternative therapies such as acupuncture;
- Appropriate management of underlying or associated cognitive, behavioral, or addiction disorders.

Documentation of compliance with a plan of therapy that includes elements from these areas is required.

Reporting of symptom severity – Severity of pain and its impact on activities of daily living (ADLs) is a key factor in determining the need for intervention. For purposes of this guideline, significant pain and functional impairment refers to pain that is at least 3 out of 10 in intensity and is associated with inability to perform at least two (2) ADLs.
Imaging Studies – All imaging must be performed and read by an independent radiologist. If discrepancies should arise in the interpretation of the imaging, the radiologist report will supersede. The results of all imaging studies should correlate with the clinical findings in support of the requested procedure.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Three artificial lumbar disc devices (activL®, Charité®, ProDisc®-L)† have been approved by the FDA through the premarket approval process. Because the long-term safety and effectiveness of these devices were not known, approval was contingent on completion of postmarketing studies. The activL (Aesculap Implant Systems), Charité (DePuy), and ProDisc-L (Synthes Spine) devices are indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at 1 level. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographs. Production under the name Charité was stopped in 2010.

A number of other artificial lumbar discs are in development or available only outside of the United States:
- The INMOTION® lumbar artificial disc (DePuy Spine) is a modification of the Charité device with a change in name under the same premarket approval. The INMOTION is not currently marketed in the United States.
- The Maverick ™ artificial disc (Medtronic) is not marketed in the United States due to patent infringement litigation.
- The metal-on-metal FlexiCore® artificial disc (Stryker Spine) has completed the investigational device exemption trial as part of the FDA approval process and is currently being used under continued access.
- Kineflex®-L™ (Spinal Motion) is a 3-piece, modular, metal-on-metal implant. An FDA advisory committee meeting on the Kineflex-L, scheduled in 2013, but was cancelled without explanation.

FDA product code: MJO.

Centers for Medicare and Medicaid Services (CMS)
Effective for services performed from May 16 through August 13, 2007, the CMS found that LADR with the Charité lumbar artificial disc is not reasonable and necessary for the Medicare population over 60 years of age. Therefore, CMS issued a national non-coverage determination for LADR with the Charité lumbar artificial disc for the Medicare population over 60 years of age.

Effective for services performed on or after August 14, 2007, CMS found that LADR is not reasonable and necessary for the Medicare population over 60 years of age; therefore, LADR is non-covered for Medicare beneficiaries over 60 years of age. For Medicare beneficiaries 60 years of age and younger, there is no national coverage determination (NCD), leaving such determinations to be made by the local contractors.

The NCD was revised in 2007 to reflect a change from non-coverage for a specific implant (the Charité), to non-coverage for the LADR procedure for the Medicare population older than 60 years of age. CMS provided this explanation,
Artificial Intervertebral Disc: Lumbar Spine

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 11/01/2017

“The original NCD for LADR was focused on a specific lumbar artificial disc implant (Charite) because it was the only one with FDA approval at that time. In the original decision memorandum for LADR, CMS stated that when another lumbar artificial disc received FDA approval CMS would reconsider the policy. Subsequently, another lumbar artificial disc, ProDisc-L, received FDA approval, which initiated the reconsideration of the NCD on LADR. After reviewing the evidence, CMS is convinced that indications for the procedure of LADR exclude the populations older than age 60; therefore, the revised NCD addresses the procedure of LADR rather than LADR with a specific manufacture’s implant.”

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

References

Policy History
Original Effective Date: 01/31/2005
Current Effective Date: 11/01/2017
12/07/2004 Medical Director review
12/21/2004 Medical Policy Committee review
01/31/2005 Managed Care Advisory Council approval
07/07/2006 Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged. Format revision. No change to policy statement.
01/01/2007 Medical Director review
01/17/2007 Medical Policy Committee approval. Coverage eligibility unchanged.
02/13/2008 Medical Director review
02/20/2008 Medical Policy Committee approval
02/04/2009 Medical Director review
02/19/2009 Medical Policy Committee approval. No change to coverage.
02/04/2010 Medical Director review
02/17/2010 Medical Policy Committee approval. No change to coverage.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Artificial Intervertebral Disc: Lumbar Spine

Policy # 00145
Original Effective Date: 01/31/2005
Current Effective Date: 11/01/2017

02/03/2011 Medical Policy Committee review
02/16/2011 Medical Policy Implementation Committee approval. No change to coverage.
02/02/2012 Medical Policy Committee review
02/15/2012 Medical Policy Implementation Committee approval. No change to coverage.
01/03/2013 Medical Policy Committee review
01/09/2013 Medical Policy Implementation Committee approval. No change to coverage.
01/09/2014 Medical Policy Committee review
01/15/2014 Medical Policy Implementation Committee approval. No change to coverage.
04/02/2015 Medical Policy Committee review
04/20/2015 Medical Policy Implementation Committee approval. No change to coverage.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
04/07/2016 Medical Policy Committee review
04/20/2016 Medical Policy Implementation Committee approval. No change to coverage.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
05/04/2017 Medical Policy Committee review
05/17/2017 Medical Policy Implementation Committee approval. No change to coverage.
07/06/2017 Medical Policy Committee review
07/19/2017 Medical Policy Implementation Committee approval. Coverage changed from investigational to eligible for coverage with criteria to adopt AIM guidelines. Adopted criterion “Age 18 to 60 years old” for lumbar artificial intervertebral disc replacement from the North American Spine Society (NASS) Coverage Policy Recommendations.

Next Scheduled Review Date: 07/2018

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>0163T, 0164T, 0165T, 22857, 22862, 22865</td>
</tr>
</tbody>
</table>
Artificial Intervertebral Disc: Lumbar Spine

Policy # 00145  
Original Effective Date: 01/31/2005  
Current Effective Date: 11/01/2017  

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>No codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICD-10 Diagnosis</td>
<td>M46.46-M46.47, M51.06, M51.26-M51.27, M51.34-M51.37, M51.46-M51.47, M51.86- M51.87, M51.9, M96.1</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:
  A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
  B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
     1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
     2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
     3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) – Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
  A. In accordance with nationally accepted standards of medical practice;
  B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
  C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.